November 28, 2020
1 min read

NYU, Columbia, Takeda partner for GI research alliance


You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Columbia University, New York University and Takeda are working together to advance research programs within gastroenterology and hepatology, according to a press release.

“Takeda looks forward to working together with the universities to successfully bring forth the most innovative, differentiated ideas to design and translate early research into therapeutics for patients with significant unmet liver and gastrointestinal disorders,” Gareth Hicks, PhD, head of the gastrointestinal drug discovery unit at Takeda, said in the release.

Through the 5-year partnership, Takeda will send funding to NYU and Columbia for pilot and feasibility studies. If their projects are successful, researchers can apply for additional funding to expand their studies.

“Through this unique partnership between academia and industry, our goal is to develop better drugs for common yet debilitating diseases of the liver and gastrointestinal system that are not well managed by existing therapies,” Nigel Bunnett, PhD, professor and chair of the department of molecular pathobiology at NYU College of Dentistry, said in the release. “It’s an exciting opportunity to cultivate projects in the lab and hopefully translate them into promising clinical treatments.”

The research alliance is asking for investigators from the two universities to submit study proposals and expects the first round of projects to begin in the fall. Takeda will also have the option to license intellectual property developed through the partnership.

“We are excited to see this agreement come to fruition as it will stimulate GI and Liver research,” Timothy Wang, MD, Silberberg Professor of Medicine and GI division chief at Columbia University Irving Medical Center, said in the release. “This alliance will hopefully accelerate breakthroughs made in research labs, with a goal of shortening the time it takes to turn initial scientific discoveries into readily available therapeutics that benefit patients.”